Abbvie Inc
NYSE: ABBV
$177.50
+$0.55 (+0.3%)
Real Time Data Delayed 15 Min.
ABBV Articles
In a new report, Cowen analysts have sights set on three major pharmaceutical stocks that they expect to have rising first-quarter earnings.
Published:
24/7 Wall St. has found four good examples of blue-chip stocks that got a little tarnished recently for one reason or another, that investors may want to reexamine.
Published:
Here are three biotech stocks that a SunTrust analyst feels could be buyout candidates, in the wake of the Pharmacyclics acquisition.
Published:
News finally broke late Wednesday that there was an official buyout of Pharmacyclics in the works by AbbVie for $21 billion.
Published:
ThinkstockAfter the markets closed Monday, Express Scripts Holding Company (NASDAQ: ESRX) reported its fourth-quarter financial results as $1.39 in earnings per share (EPS) and $26.31 billion in...
Published:
One area that makes sense for growth investors is the large cap pharmaceuticals. Here are some the top pharmaceutical stocks to buy now according to Jefferies.
Published:
Neurocrine Biosciences has announced that it will have another public offering of its common stock to raise roughly $225 million.
Published:
Monday's top analyst upgrades, downgrades and initiations include AbbVie, Alcoa, Apple, Deckers Outdoor, Dish Network, Pfizer and Petrobras.
Published:
If there is one thing that the pharmaceutical industry tries to shy away from it is the controversy over the costs of some of the drugs on the market today.
Published:
Tuesday after the U.S. markets close, Gilead Sciences will report its fourth-quarter financial results.
Published:
AbbVie reported better-than-expected fourth-quarter financial results Friday before the markets open.
Published:
Gilead Sciences was picked up by Anthem to provide its hepatitis C drug as the primary option for patients.
Published:
Is it possible that Gilead Sciences is already coming back into favor after just a week of being in the doghouse?
Published:
Analysts are beginning to make their calls for what the future will hold for Gilead Sciences, AbbVie and Express Scripts.
Published:
AbbVie and Express Scripts have entered into an exclusive agreement under which Express Scripts will distribute AbbVie's hepatitis treatment.
Published: